Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant.
Hudgens S, Floden L, Blackowicz M, Jamieson C, Popova V, Fedgchin M, Drevets WC, Cooper K, Lane R, Singh J.
J Affect Disord. 2021 Feb 15;281:767-775. doi: 10.1016/j.jad.2020.11.066. Epub 2020 Nov 14.
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D, Forbes M, Haumann HM, Hellerstein DJ, Hoppe AI, Husain MI, Jelen LA, Kamphuis J, Kawasaki J, Kelly JR, Key RE, Kishon R, Knatz Peck S, Knight G, Koolen MHB, Lean M, Licht RW, Maples-Keller JL, Mars J, Marwood L, McElhiney MC, Miller TL, Mirow A, Mistry S, Mletzko-Crowe T, Modlin LN, Nielsen RE, Nielson EM, Offerhaus SR, O'Keane V, Páleníček T, Printz D, Rademaker MC, van Reemst A, Reinholdt F, Repantis D, Rucker J, Rudow S, Ruffell S, Rush AJ, Schoevers RA, Seynaeve M, Shao S, Soares JC, Somers M, Stansfield SC, Sterling D, Strockis A, Tsai J, Visser L, Wahba M, Williams S, Young AH, Ywema P, Zisook S, Malievskaia E.
N Engl J Med. 2022 Nov 3;387(18):1637-1648. doi: 10.1056/NEJMoa2206443.
Bifidobacterium breve CCFM1025 attenuates major depression disorder via regulating gut microbiome and tryptophan metabolism: A randomized clinical trial.
Tian P, Chen Y, Zhu H, Wang L, Qian X, Zou R, Zhao J, Zhang H, Qian L, Wang Q, Wang G, Chen W.
Brain Behav Immun. 2022 Feb;100:233-241. doi: 10.1016/j.bbi.2021.11.023. Epub 2021 Dec 4.
Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery-Asberg Depression Rating Scale and the 9-item Patient Health Questionnaire.
Kern Sliwa J, Naranjo RR Jr, Turkoz I, Petrillo MP, Cabrera P, Trivedi M.
CNS Spectr. 2024 Jun;29(3):176-186. doi: 10.1017/S1092852924000105. Epub 2024 Apr 1.
Psychological Treatment of Comorbid Insomnia and Depression: A Double-Blind Randomized Placebo-Controlled Trial.
Blom K, Forsell E, Hellberg M, Svanborg C, Jernelöv S, Kaldo V.
Psychother Psychosom. 2024;93(2):100-113. doi: 10.1159/000536063. Epub 2024 Jan 29.
Montgomery-Asberg Depression Rating Scale factors in treatment-resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine.
Borentain S, Gogate J, Williamson D, Carmody T, Trivedi M, Jamieson C, Cabrera P, Popova V, Wajs E, DiBernardo A, Daly EJ.
Int J Methods Psychiatr Res. 2022 Dec;31(4):e1927. doi: 10.1002/mpr.1927. Epub 2022 Jun 24.
Relationship between the Hamilton Depression Rating Scale and the Montgomery-Asberg Depression Rating Scale in depressed elderly: a meta-analysis.
Heo M, Murphy CF, Meyers BS.
Am J Geriatr Psychiatry. 2007 Oct;15(10):899-905. doi: 10.1097/JGP.0b013e318098614e.
Validation of Bangla Montgomery Asberg Depression Rating Scale (MADRSB).
Soron TR.
Asian J Psychiatr. 2017 Aug;28:41-46. doi: 10.1016/j.ajp.2017.03.019. Epub 2017 Mar 22.
Reliability and validity of the telephone-based version of the Montgomery-Asberg depression rating scale for assessing depression in individuals with primary brain tumour.
Harris G, Jones S, Pinkham MB, Lion KM, Ownsworth T.
Disabil Rehabil. 2024 Mar;46(6):1158-1166. doi: 10.1080/09638288.2023.2191015. Epub 2023 Apr 5.
Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials.
Akbar D, Rhee TG, Ceban F, Ho R, Teopiz KM, Cao B, Subramaniapillai M, Kwan ATH, Rosenblat JD, McIntyre RS.
CNS Drugs. 2023 Oct;37(10):867-881. doi: 10.1007/s40263-023-01032-5. Epub 2023 Oct 4.
